These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 20977322

  • 1. Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder.
    Bobo WV, Shelton RC.
    Expert Rev Neurother; 2010 Nov; 10(11):1637-58. PubMed ID: 20977322
    [Abstract] [Full Text] [Related]

  • 2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
    Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, Kujawa M, Mahmoud R.
    Bipolar Disord; 2009 Dec; 11(8):827-39. PubMed ID: 19922552
    [Abstract] [Full Text] [Related]

  • 4. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder.
    Han C, Lee MS, Pae CU, Ko YH, Patkar AA, Jung IK.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug 15; 31(6):1219-23. PubMed ID: 17532106
    [Abstract] [Full Text] [Related]

  • 5. Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients.
    Malempati RN, Bond DJ, Yatham LN.
    Int Clin Psychopharmacol; 2008 Mar 15; 23(2):88-94. PubMed ID: 18301123
    [Abstract] [Full Text] [Related]

  • 6. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder.
    Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V.
    Biol Psychiatry; 2010 Jul 15; 68(2):156-62. PubMed ID: 20227682
    [Abstract] [Full Text] [Related]

  • 7. Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: a prospective study of 3-year outcomes.
    Malempati RN, Bond DJ, Kunz M, Malemati C, Cheng A, Yatham LN.
    Int Clin Psychopharmacol; 2011 May 15; 26(3):146-50. PubMed ID: 21372721
    [Abstract] [Full Text] [Related]

  • 8. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.
    J Clin Psychiatry; 2009 Oct 15; 70(10):1397-406. PubMed ID: 19906343
    [Abstract] [Full Text] [Related]

  • 9. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone.
    Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz N, Bonet P.
    World J Biol Psychiatry; 2008 Oct 15; 9(3):219-24. PubMed ID: 18609430
    [Abstract] [Full Text] [Related]

  • 10. One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.
    Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.
    Clin Schizophr Relat Psychoses; 2012 Jul 15; 6(2):61-8. PubMed ID: 22776632
    [Abstract] [Full Text] [Related]

  • 11. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
    Arunpongpaisal S, Srisurapanont M, Kongsakon R, Kitiwattanagul K, Samanwongthai U.
    J Med Assoc Thai; 2010 Mar 15; 93(3):343-50. PubMed ID: 20420110
    [Abstract] [Full Text] [Related]

  • 12. Explicit review of risperidone long-acting injection prescribing practice.
    Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.
    J Clin Pharm Ther; 2011 Dec 15; 36(6):651-63. PubMed ID: 22023342
    [Abstract] [Full Text] [Related]

  • 13. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S.
    Expert Rev Neurother; 2009 Jan 15; 9(1):9-31. PubMed ID: 19102665
    [Abstract] [Full Text] [Related]

  • 14. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.
    Pharmacopsychiatry; 2007 Nov 15; 40(6):257-63. PubMed ID: 18030649
    [Abstract] [Full Text] [Related]

  • 15. Olanzapine: new indication. Prevention of bipolar disorder: unconvincing trials.
    Prescrire Int; 2005 Aug 15; 14(78):140-2. PubMed ID: 16106596
    [Abstract] [Full Text] [Related]

  • 16. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.
    De la Gándara J, San Molina L, Rubio G, Rodriguez-Morales A, Hidalgo Borrajo R, Burón JA.
    Expert Rev Neurother; 2009 Oct 15; 9(10):1463-74. PubMed ID: 19831836
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
    Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L.
    Int Clin Psychopharmacol; 2010 May 15; 25(3):149-54. PubMed ID: 20305567
    [Abstract] [Full Text] [Related]

  • 18. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
    Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A.
    Curr Med Res Opin; 2010 Mar 15; 26(3):501-9. PubMed ID: 20014981
    [Abstract] [Full Text] [Related]

  • 19. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
    Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van den Berg LT, Postma MJ.
    Clin Ther; 2010 Jan 15; 32(1):108-18. PubMed ID: 20171417
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.
    Vieta E, Montgomery S, Sulaiman AH, Cordoba R, Huberlant B, Martinez L, Schreiner A.
    Eur Neuropsychopharmacol; 2012 Nov 15; 22(11):825-35. PubMed ID: 22503488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.